Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.

Jendle, Johan; Ericsson, Åsa; Gundgaard, Jens; Møller, Jonas Bech; Valentine, William J; Hunt, Barnaby

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.

Jendle, Johan; Ericsson, Åsa; Gundgaard, Jens; Møller, Jonas Bech; Valentine, William J; Hunt, Barnaby.

Afiliação

Jendle J; Institute of Medical Sciences, Örebro University, Örebro, Sweden. johan.jendle@oru.se.
Ericsson Å; Novo Nordisk Scandinavia AB, Malmö, Sweden.
Gundgaard J; Novo Nordisk A/S, Søborg, Denmark.
Møller JB; Novo Nordisk A/S, Søborg, Denmark.
Valentine WJ; Ossian Health Economics and Communications, Basel, Switzerland.
Hunt B; Ossian Health Economics and Communications, Basel, Switzerland.

Diabetes Ther ; 12(1): 373-388, 2021 Jan.

Article em En | MEDLINE | ID: mdl-33306169

Palavras-chave

Diabetes complications; Diabetes self-management; Diabetes technology; Digital health; Health technology assessment; Healthcare economics; Hypoglycemia; Insulin therapy; Type 1 diabetes; eHealth

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google